{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.5","upperLimit":"14.8","value":"4.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"46"}],"units":"Participants"}],"description":"The best overall response rate (percentage) is the percent of patients whose best response was Complete Response (CR) or Partial Response (PR) as defined by RECIST 1.1 criteria. Percentage of successes will be estimated by 100 times the number of successes divided by the total number of evaluable patients.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive 160 mg enzalutamide orally once daily (1 cycle=28 days). Patients will remain on therapy until progression of disease or development of unacceptable toxicities or patient or physician withdrawal. Patients will undergo radiographic imaging every 2 months while on study treatment in order to determine response.","id":"OG000","title":"Enzalutamide"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Up to 32 weeks","title":"Best Overall Response Rate","type":"PRIMARY","unitOfMeasure":"percentage of patients"}